A pooled analysis of the cardiac events in the trastuzumab adjuvant trials.

ABSTRACT:

Background

Trastuzumab-associated cardiotoxicity remains an issue for patients with HER2-positive breast cancer. This pooled analysis of 3 adjuvant trials investigated the incidence, timing, impact on treatment completion, and risk factors for trastuzumab-associated cardiotoxicity.

Methods

This is an individual patient data level pooled analysis of HERA, NSBAP B-31, and NCCTG 9831 (Alliance Trials). Definitions of cardiac events were as per each individual study.

Results

A total of 7445 patients enrolled in the 3 trials were included in the analysis, of which 4017 were in the trastuzumab and 3428 in the control (observation) arms, respectively. Median follow-up exceeded 10 years (119.2-137.2 months). Nearly all patients (97.4%) in the trastuzumab arms received anthrac

SUBMITTER: de Azambuja E 

PROVIDER: S-EPMC6989393 | biostudies-literature | 2020 Jan

REPOSITORIES: biostudies-literature